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Abstract
Background: Normal pubertal ovary displays all stages of follicular development and a biased BAX/BCL2 protein ratio
in favor of pro-apoptotic BAX protein comparable to the adult ovary. However, adolescents suffering malignant extra-
gonadal disease show a limited follicle development after cytotoxic drug treatment and a reduced capacity of in vitro
follicle growth. We evaluated the expression of pro- and anti-apoptotic members of the BCL2 gene family, the FAS/
FAS-L proteins from the extrinsic apoptosis pathway, the germ-cell-specific marker VASA, the pluripotency marker
OCT3/4, and markers of early and late apoptosis in the ovary of pubertal patients with malignant extra-gonadal disease,
which received or not pre-surgery chemotherapy, entering a cryopreservation program.
Results: Ovarian biopsies from 12 adolescent girls were screened for follicle count and expression of VASA, OCT3/4,
BAX, BCL2, MCL1L and S, cleaved-BID, FAS/FAS-L and CASPASE 3 through immunohistochemistry, western blot and RT-
PCR. All stages of folliculogenesis, from primordial to antral follicle, were present in all 12 patients analyzed. VASA and
most of the screened apoptosis-related genes showed a pattern of immune-expression comparable to that previously
reported. OCT3/4 showed a cytoplasmic localization in the great majority of the primordial follicles; however, in some
cases the localization was nuclear. In addition, OCT3/4B showed a significant reduction compared to OCT3/4A.
Unexpectedly, BCL2 was detected at all stages of folliculogenesis, associated to the Balbiani’s body in the primordial
follicles, regardless of whether patients had or had not received chemotherapy, ruling out the possibility that its
expression is a protective response to chemotherapy.
Conclusions: These findings reveal new information on the morphological status of the follicular reserve and the
expression of apoptosis-related genes in histologically normal adolescent ovary from patients undergoing extragonadal
cancer. The unexpected expression of apoptosis-inhibiting BCL2 protein, both in patients that had or had not received
chemotherapy, opens a new avenue for thorough investigations. Moreover, the nuclear localization of OCT3/4 protein
in primordial follicle-enclosed oocytes suggests a possible increased activity of ovarian stem cells in response to
chemotherapy and/or extragonadal cancer. This new information can be essential for a better managing of in vitro
culture of follicles that can be removed by filtration from preserved ovarian tissue, especially in girls that entered a
cryopreservation program.
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Background
In women, the establishment of the germinal reserve
takes place during fetal life through the interplay be-
tween germ cell proliferation and death in the develop-
ing ovary. As soon as proliferation begins to increase the
1000–2000 primordial germ cells that reached the devel-
oping ovary, to produce around 7 × 106 potential oocytes
at mid-fetal life, a counterbalance mechanism of cell
death, executed mainly through apoptosis, takes place.
The size of the resting primordial follicle reserve is de-
termined by the fourth month of fetal life, as a conse-
quence of cell proliferation/cell death balance, when
primordial follicle development begins. Germ cell attri-
tion particularly occurs in the transition from meiotic
prophase I to primordial follicle formation through
massive apoptosis and continues until the end of gesta-
tion, leading the developing ovary to contain just around
1-2 × 106 primordial follicles at birth; a wasteful cellular
loss of almost 85% of the potential 7 × 106 oocyte popu-
lation reached at mid gestation [8, 16]. Death is mainly
driven through intrinsic apoptosis mechanisms governed
by a concerted expression of BCL2 gene family members
[1] acting in the germ cell proper throughout fetal life
[4, 36]. In the adult ovary, germ cell elimination through
apoptosis will continue, both in resting and growing
follicles, acting mainly in granulosa cells surrounding
the oocyte, until the germinal reserve is exhausted and
women enter menopause [3]. Although apoptosis occurs
under physiological conditions and contributes to main-
tain cellular homeostasis, an alteration in its regulation
may lead to tissue alterations. For example, it was ob-
served that a decrease in apoptosis is present in endo-
metriosis and ovarian cancer [7, 14, 37].
In the last 20 years, several studies analyzing the ex-
pression of BCL2-family genes have focused mainly in
the fetal and adult ovary, showing that pro-apoptotic
members prevail throughout ovarian development, de-
termining the known high rates of oocyte elimination
whereas anti-apoptotic genes, like BCL2 and MCL1,
show a time-restricted pattern of expression and act as
key regulators determining survival and preserving germ
cell availability at proliferative time-points [18, 35, 36].
The infant and adolescent ovary deserved less attention
probably due to the limited availability of samples.
Histological studies performed in the 70s’ have shown
that all stages from primordial to early-antral follicles
are detected in the infant ovary [27, 28], with the excep-
tion of the pre-ovulatory follicle that appears at the on-
set of puberty [29], showing that follicle growth is by
and large comparable to the adult ovary. However, fol-
licle development is inhibited in children with abdom-
inal tumors or treated with cytotoxic drugs or
irradiation [20, 21]. More recently, an analysis of chil-
dren and adolescent ovary from patients with malignant
or chronic illness showed a high proportion of abnormal
non-growing follicles with reduced capacity for in vitro
development [6]. We have previously analyzed BCL2
and BAX proteins in normal infant and pubertal ovary
showing that both proteins behave as in fetal life as far
as the oocyte remains in the primordial resting reserve,
whereas in follicles entering the growing pool gene ex-
pression moves from the germ cell to granulosa cells
with an expression pattern comparable to the adult
ovary [2]. Nevertheless, no data exist so far regarding
the behavior of apoptosis-related proteins in the
adolescent ovary from patients suffering malignant
extra-gonadal disease whose ovary has been shown to
have limited follicle development after cytotoxic drug
treatment or irradiation [20, 21] and display a reduced
capacity of in vitro follicle development [6].
The aim of this study was to evaluate the expression of
pro- and anti-apoptotic members of the BCL2 gene family,
the FAS/FAS-L proteins from the extrinsic apoptosis
pathway, the germ-cell-specific marker VASA, the pluripo-
tency marker OCT3/4, and markers of early- and late-
apoptosis in the ovary of pubertal patients with malignant
extra-gonadal disease, which received or not pre-surgery
chemotherapy, entering a cryopreservation program.
Results
Follicle count in cortical ovarian fragments
Active folliculogenesis was found in all samples ana-
lyzed. The ovary from the 7 years old patient (pre-puber-
tal, sample 1) showed primordial, primary, secondary,
antral and atretic antral follicles (Table 1). The ovaries
from 12 to 19 years old pubertal patients showed all fol-
licular stages from primordial follicle to antral follicles,
atretic antral follicles and luteum and albicans bodies
(Table 1). Although tissue volume and the total follicle
count showed a high variability among patients, primor-
dial follicle was the more abundant follicular stage repre-
senting > 50% of the total count, reaching more than
80% in most cases (Table 1). Mean percent number of
primordial follicles did not show statistical differences
between patients that had (90.25 ± 10.53%) or had not
(82.63 ± 17.72%) received chemotherapy.
Expression of VASA and OCT3/4 proteins
Germ-cell-specific VASA protein was detectable in the
cytoplasm of oocyte in primordial and primary follicles
(Fig. 1a); no signal for VASA was found in somatic
stratum. Advanced primordial follicles showed VASA
protein in a para-nuclear localization corresponding to
Balbiani’s vitelline body (Fig. 1b). In primary follicles,
VASA distributed throughout the oocyte cytoplasm.
VASA immune detection was corroborated through pro-
tein analysis (Fig. 1c) in variable amounts among patients
(Fig. 1d) and its expression was significantly diminished
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compared to BID, MCL-1 L, BCL2 and BAX proteins
(Tukey test, α:0.05; p < 0.0001) (Fig. 2).
OCT3/4 protein was mainly detected in the cytoplasm
of oocyte in primordial, primary and secondary follicles
(Fig. 3). However, nuclear signals in occasional primor-
dial follicle-enclosed oocytes were also detected in pa-
tients 1, 6 and 9 (Fig. 3a).
Expression of intrinsic apoptosis proteins
Immunolocalization of intrinsic apoptosis proteins was
restricted to the follicular compartment without detec-
tion in the interstitial environment. The pro-apoptotic
BAX protein was detectable in all follicular stages. BAX
signal was detected both in the cytoplasm of the oocyte
as in granulosa cells from early primordial to secondary
follicle (Fig. 4a-c); in antral follicles, BAX detection was
mainly restricted to granulosa. Corpora lutea and albi-
cans bodies also displayed BAX signal (Fig. 4d). BAX
protein immunoblot was positive in all patients with
variable levels among them (Fig. 4e, f ). Immunolabelling
with anti-BCL2 was restricted to the oocyte in early
primordial follicles (Fig. 5a); it was detectable in the oo-
cyte and granulosa cells of primordial/primary follicles
(Fig. 5b) and mostly detected in granulosa cells in more
advanced stages (Fig. 5c, d). BCL2 distributed heteroge-
neously in the oocyte cytoplasm, in a para-nuclear
localization, in primordial and primordial/primary folli-
cles (Fig. 5a, b). BCL2 protein immunoblot was positive
in all patients, although highly variable among them
(Fig. 5e, f ). Statistical analysis did not show significant
differences between BAX and BCL2 proteins (Fig. 2).
MCL-1 protein was detected in the cytoplasm of oo-
cytes in early primordial follicles with a heterogeneous
distribution (Fig. 6a). In more advanced stages, e.g.,
primary, secondary and preantral follicles, the signal
remained in the oocyte cytoplasm and it was also found
in granulosa cells (Fig. 6b, c). Western blot analysis
distinguished between anti-apoptotic MCL-1 L and pro-
apoptotic MCL-1S variants (Fig. 6d). Both MCL-1 iso-
forms were detected in all cases, with the exception of
patient 9. In the majority of cases (patients 1–8 and 10)
the anti-apoptotic isoform prevailed and only in patients
11 and 12 the pro-apoptotic variant was favored in the
face of the anti-apoptotic isoform (Fig. 6e). The statis-
tical analysis for both isoforms did not show significant
differences between them (Fig. 2).
The pro-apoptotic cleaved-BID protein was detected
mainly in granulosa cells and oocytes in primordial and
primary follicles (Fig. 7a, b) and the signal still persisted in
the oocyte cytoplasm of some secondary follicles (Fig. 6c).
Cleaved-BID protein immunoblot by western blot was
positive in all cases with variable amount among patients
(Fig. 7d, e). No differences in cleaved-BID recovery was
found when compared with other proteins, except with
VASA (Tukey test, α: 0.05; p < 0.0001) (Fig. 2).
Immunolocalization of extrinsic FAS/FAS-L proteins
FAS/FAS-L proteins were positive in primordial, primary
and secondary follicles both in oocyte and granulosa
cells (Fig. 8a-d) and they were detected in antral follicles,
corpus luteum and the albicans body as well.
Caspase-3 detection and TUNEL assay
Pro-caspase 3 was positive in some primordial follicles
(Fig. 9a). The protein was also detected in some primary
and secondary follicles. Atretic antral follicles were nega-
tive (Fig. 9b). The majority of primordial follicles were
positive for cleaved caspase-3 (Fig. 9c) which was also
Table 1 Follicle count and follicle classification in adolescent human ovarian biopsies from patients with extra-gonadal malignant
disease








Primordial Primary Secondary Antral Others
1 343 30 4 1 1 atretic 100 379 90,5
2 1060 68 7 1 2 luteum bodies 23.4 1138 93.14
3 56 47 2 0 2 atretics; 2 luteum bodies; 1 albicans body 84 110 50,9
4 533 4 1 0 4 luteum bodies 80 542 98.3
5 1295 22 6 0 2 atretics, 1 luteum body, 2 albicans bodies 52.5 1328 97.52
6 3555 154 7 1 1 atretic; 1 luteum body; 2 albicans bodies 101,5 3721 95,5
7 326 50 5 3 1 atretic; 2 luteum bodies; 3 albicans body 192 390 83,6
8 4081 73 17 0 1 atretic; 1 luteum body; 1 albicans body 108 4174 97,8
9 2178 1 1 0 1 albicans body 360 2181 99.9
10 72 13 3 0 1 luteum body 94.5 89 80.9
11 111 26 6 0 3 atretics y 1 luteum body 168 147 75.5
12 233 59 20 1 1 atretic y 2 luteum bodies 21 316 73.73





Fig. 1 Detection of germ-cell-specific VASA protein in human ovary. a Primordial follicles VASA positive in cytoplasm oocyte (200X). b Primordial
follicle VASA positive with para-nuclear localization corresponding to Balbiani’s vitelline body (1000X). c) Western blot analysis of human ovarian
VASA protein (79 kD). d Western blot quantification of VASA protein. This protein was detectable in all samples with variable intensity
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detected in primary, secondary and atretic antral follicles
(Fig. 9d). Apoptotic cells were detected by TUNEL in
the innermost layer of granulosa cells in antral follicles,
mainly in late antral stage. A few apoptotic theca cells
were positive in antral follicles (Fig. 9e, f ).
mRNA expression in adolescent ovary
The expression of VASA, OCT3/4 A and B, BAX, BCL2,
MCL-1 L and S, BID, BCL-XL, FAS, FAS-L and CASPASE
3 were similar among the analyzed patients. Most of the
genes did not show significant differences, except OCT3/
4B whose expression was significantly diminished with re-
spect to OCT3/4A, BCL2 and MCL-1S expression (Tukey,
α:0.05; p < 0.0001) (Fig. 10b).
Discussion
Our current knowledge about the infant and teen
human ovary is still scarce, most likely due to difficulties
in obtaining samples from children and adolescents.
Besides reports on the general histology performed in
the 70s’ [20, 21, 27–29], a few studies have been pub-
lished more recently analyzing the ovarian histogenesis,
follicular composition and immunolocalization of apop-
tosis- and germline-related proteins [2, 6, 15].
The ovarian reserve and folliculogenesis in the pubertal
ovary
Ovarian sections from all 12 patients examined showed
an active folliculogenesis and a high density of primor-
dial follicles. The wide variability of primordial follicles,
ranging from 50 to 99% of the total follicular pool,
among patients (cf. Table 1) may be attributed to the
random and the heterogeneous distribution of follicles
in the human ovary [16, 32], especially considering that
primordial follicles are normally found in clusters [31].
In agreement with previous studies [15], pubertal ovaries
showed all follicular stages, including antral follicles and
luteum and albicans bodies as well, confirming the
Fig. 2 Western blot statistical analysis for VASA, BAX, BCL2, MCL-1 and cleaved-BID proteins in human ovary from pre- and pubertal oncological
patients. Each bar represents a mean ± s.d. Different letters over the bars indicate significant differences between samples (Tukey, α: 0,05, p < α)
Fig. 3 Immune-localization of OCT3/4 protein in adolescent human ovarian tissue. a Primordial follicles OCT3/4 positive. Note some follicles were
positive in oocyte cytoplasm and others were positive in nucleus (Arrows head) (100X). b Detailed view of a typical primordial follicle; OCT3/4
protein was detectable in the cytoplasm of oocyte (1000X)
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Fig. 4 Detection of pro-apoptotic BAX protein in adolescent human ovary. a Primordial follicles show BAX protein in granulosa cells and in the
germ-cell proper (200X). b The signal persists in primary follicle (1000X) and c) secondary follicle (400X). d Partial view of a luteum body positive
for BAX (400X). e Western blot analysis of human ovarian BAX protein (23 kD). f Western blot quantification of BAX protein. This protein was
detectable in all samples. GLC: granulosa-luteal cells
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Fig. 5 (See legend on next page.)
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post-menarche beginning of cyclic follicle recruitment.
The only pre-pubertal ovary included in this report, a 7
years old patient, showed that histogenesis was still in
progress with initial follicle recruitment. We did not ob-
serve significant differences in the percentage of primor-
dial follicles between patients that had or had not
received chemotherapy before surgery. Although chemo-
therapy drugs are known to be highly toxic and they can
upregulate the PI3K pathway leading to a wave of fol-
licular recruitment and growth that burnout the ovarian
reserve [23], our results agreed with Duncan et al. [15]
in that the adolescent ovary displays follicles irrespective
of treatment history.
VASA, OCT3/4 and apoptosis-related proteins in the
adolescent ovary
VASA expression was restricted to the cytoplasm of oo-
cytes in primordial and primary follicles in all 12 patients
analyzed. In primordial follicles, VASA showed a para-nu-
clear localization corresponding to Balbiani’s vitelline
body, whereas in primary follicles VASA distributed
homogeneously in the cytoplasm. No difference with pre-
vious observations was detected [2]. It has been proposed
that VASA expression follows a stage-specific immune
detection pattern that reflects the main changes during
fetal ovarian development [4, 5, 12, 34]. In post-natal ovar-
ies, we have found that VASA continues to express after
birth until puberty in the resting primordial follicle re-
serve, associated with the Balbiani’s body; its expression
pattern relates mainly to the follicular stage rather than to
the stage of development [2]. The association or not of
VASA to the Balbiani space may relate to the final fate of
the germ cell [4]. In support, the ovary of Lagostomus
maximus, a rodent with no germ cell attrition or
apoptosis-dependent follicular atresia through constitutive
expression of BCL2, shows a low abundance of Balbiani-
(See figure on previous page.)
Fig. 5 Detection of anti-apoptotic BCL2 protein in adolescent human ovary. a Primordial follicle and b) primordial/primary follicle BCL2 positive.
BCL2 was heterogeneously distributed in a para-nuclear localization in the oocyte cytoplasm (Arrow heads) (1000X). c Secondary follicles show
BCL2 protein in granulosa cells and in the germ-cell proper (200X). d Antral follicle (partial view), BCL2 is detectable in granulosa cells (1000X). e
Western blot analysis of human ovarian BCL2 protein (23 kD). f Western blot quantification of BCL2 protein. It was detectable in all samples with
variable intensity. O: oocyte; GC: granulosa cells
Fig. 6 Detection of MCL-1 protein in adolescent human ovary. a Primordial follicle (1000X), b primary follicle (1000X) and c) secondary follicle
(200X) show MCL-1 protein in granulosa cells and in the germ-cell proper. d Western blot analysis for both isoforms of MCL-1, the anti-apoptotic
MCL-1 L (40 kD) and the pro-apoptotic MCL-1S (32 kD). e Western blot quantification of MCL-1 L and MCL-1S proteins. Both isoforms were
detectable in all samples with variable intensity
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associated VASA throughout development [26]. The pres-
ence of anti-apoptotic BCL2 in Balbiani’s body (see below)
in patients with extragonadal cancer might influence the
survival of the primordial follicle.
OCT3/4 protein was detected from primordial to sec-
ondary follicles in the adolescent ovary with an expres-
sion of isoform A significantly increased in the face of
isoform B (cf. Fig. 10b). Moreover, OCT3/4-A gene activ-
ity showed a tendency to be increased in patients that
received chemotherapy compared to those that did not
(Fig. 11). Although no statistical differences were de-
tected among these groups, the small size of samples
must be considered. OCT3/4 is a POU domain tran-
scription factor involved in the regulation of cell pluripo-
tency and renewal [25]. The expression of OCT3/4
isoforms has been related to two different populations of
stem cells residing in the ovarian surface epithelium:
very small embryonic-like stem cells (VSELs), small-sized
pluripotent cells that express nuclear OCT3/4-A and
give rise to ovarian stem cells (OSCs), slightly bigger
than VSELs, expressing cytoplasmic OCT3/4-B [9, 10].
The detection of nuclear OCT3/4 in three patients in
this study together with the increased expression of
isoform A versus isoform B suggest an increased activity
of stem cells in these ovaries. If the presence of nuclear
OCT3/4 is a response to chemotherapy, to the presence
of extra-gonadal cancer or both requires further analysis.
Only two of the three patients who presented nuclear
OCT3/4 had received chemotherapy. Both chemother-
apy and the presence of cancer in any organ of the body
compromise homeostasis and may be sufficient to trig-
ger the activity of stem cells [11].
Our analysis of BCL2 family proteins showed that the
immunolocalization pattern of pro- and anti-apoptotic
members was related to follicular stage. BAX and MCL-1
were detectable throughout folliculogenesis whereas
cleaved-BID was restricted to the follicular reserve. The
pattern of immunolocalization of BAX was similar to that
we previously observed in infant, pubertal and adult ovar-
ies [2, 3]. Unexpectedly, the anti-apoptotic BCL2 protein
showed an immunolocalization quite different to that pre-
viously reported. This protein was detectable throughout
folliculogenesis, including primordial and primary follicles
of the germinal reserve. The expression of BCL2 in the
primordial reserve both in patients that had or had not
received chemotherapy rules out the possibility that BCL2
Fig. 7 Detection of pro-apoptotic cleaved-BID protein in adolescent human ovary. a Primordial follicle and b) primary follicle cleaved-BID positive
(1000X). c Secondary follicles show cleaved-BID protein in granulosa cells and in the germ-cell proper (200X). d Western blot analysis of human
ovarian cleaved-BID protein (22 kD). It was detectable in all samples. e Western blot quantification of cleaved-BID protein. It was detectable in all
samples with variable intensity. O: oocyte; GC: granulosa cells
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expression may be linked to a chemo-treatment re-
sponse, supporting the idea that it is related to the
presence of an extragonadal tumor. In previous studies,
BCL2 protein was not detectable in dormant primordial
follicles and primary follicles, leaving the resting
reserve in postnatal ovary from individuals not under-
going a cancer situation. It became detectable in the
somatic stratum from secondary follicles, as well as in
preantral and antral follicles, co-existing with BAX pro-
tein [2, 3]. It is worth to note that BCL2 becomes
detectable when proliferative processes occur, i.e. at the
moment in which the number of oogonia is actively in-
creasing through mitosis in the fetal ovary or when
granulosa cells actively divide during the growing fol-
licular phase in the infant/pubertal ovary [2, 4, 18, 35,
36]. In the light of the expression pattern of OCT3/4
found in these patients, especially the presence of nu-
clear expression (see above), the unexpected detection
of BCL2 in the germinal reserve could be a response to
an increased proliferative activity of ovarian stem cells.
Alternatively, BCL2 expression could be due to a pro-
tective response to the presence of an extragonadal
pathological process. Cancer is, per se, a disease that in-
duces oxidative stress, thus generating toxic effects on nor-
mal cells, combined with anoxia and deficits in nutrients
and antioxidants that cannot compensate the production
of free radicals [19, 33]. It is tempting to think that germ
cells are responding to survive in the stressing environ-
ment. BCL2 detection could be of good prognosis for an
eventual future recovery of the gametogenic capacity, con-
sidering the protective concurrent expression of OCT3/4.
The FAS/FAS-L system involved in the extrinsic
pathway of apoptosis, displayed an immunohistochemi-
cal pattern comparable to that found for the apoptosis-
inducing BAX protein. This system has deserved little
attention, and a few contributions explored its role in
the human ovary [3, 13, 24, 30]. It is worth to note that
both FAS protein and its ligand, FAS-L, displayed
strong immune labeling in the somatic stratum of an-
tral and atretic follicles and the corpus luteum. These
observations reinforce the idea that FAS/FAS-L acts
mainly in follicular regression and atresia [24].
The occasional presence of cleaved-caspase 3 in
primordial follicles suggests that the process of cell
damage would be already at play in some follicles that
are going to be recruited to the growing pool and most
likely they will enter atresia during or before reaching
the antral stage. Only antral follicles, and especially
fully-grown follicles, as well as atretic follicles, showed
TUNEL and cleaved-caspase 3 positive signals in gran-
ulosa and theca cells, indicating an active apoptotic
process accompanying follicular atresia.
Fig. 8 Immunostaining for both FAS/FAS-L proteins in adolescent human ovary. a Primary follicle (400X) and b) secondary follicle (400X) were
positive for FAS protein. In the last one, it was detectable in oocyte and granulosa cells. c Primordial follicle positive for FAS-L in cytoplasm
oocyte (1000X). d Secondary follicle positive for FAS-L in oocyte and granulose cells (400X). O: oocyte; GC: granulosa cells
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Final considerations
A long-held tenet supports the idea that mammals’
female are born with a finite and non-renewable endow-
ment of oocytes. Nevertheless, the detection in 2004 by
Tilly’s group [22] of a small cell population in the adult
mouse ovary residing in the ovarian surface epithelium
and expressing meiotic markers fueled the possibility of
female neo-oogenesis after birth. Fourteen years later,
although some controversies still persist, the presence of
ovarian stem cells that could act to regenerate the germ-
line is a proven fact. The detection, in this report, of
anti-apoptotic markers and nuclear OCT3/4 expression
in the primordial reserve of adolescent patients undergo-
ing extragonadal cancer adds new information on stem
cell activity in response to stress conditions and
illuminates an encouraging perspective for the restor-
ation of fertility through the development of reliable
culture techniques for in vitro re-establishment of the
gametogenic capacity in girls that entered a cryopreser-
vation program.
Methods
Recovery of ovarian samples
A total of 12 patients entering an ovary cryopreservation
program at Hospital de Niños “Ricardo Gutiérrez”, Bue-
nos Aires city, were included in this study. All patients
had suffered extra-gonadal malignant disease and 6 of
them received chemotherapy before surgery. In all these
6 patients, samples were taken one month after the end
of treatment. At the time of cryopreservation, the
Fig. 9 Immunodetection for CASPASA-3 and TUNEL-assayed in human ovary. a Primordial follicles positive (arrow head) and negative for pro-
caspase 3 (400X). b Partial view of an atretic antral follicle negative for pro-caspase 3 (200X). c Panoramic view of cortex ovary showing
abundance of primordial follicles positive for cleaved caspase 3 protein (100X). d Atretic antral follicle was positive for cleaved caspase 3 in
granulosa and thecal cells (200X). e Apoptotic cells were detected in granulosa and thecal cells of antral follicles (400X). f Partial view of an atretic
antral follicle with granulosa cells TUNEL positive (1000X). A: antrum; GC: granulosa cells, IT: internal theca
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patients were aged between 7 and 19 years and one of
them (aged 7 years old) was pre-pubertal (Table 2). At the
surgery room, the entire ovarian cortex was excised for
cryopreservation and 3 small fragments (1.0 × 0.5 mm)
were recovered for research purposes. One fragment was
fixed in 10% buffered formalin; a second fragment was
stored at − 80 °C and a third one was immersed in 1ml of
RNA later. All patients had a normal ovary histological
diagnosis from the Pathology Service of the Hospital Ri-
cardo Gutiérrez. The protocol for ovarian cryopreserva-
tion and donation of samples for research was reviewed
and approved by the Research Ethics Committee of
Universidad Maimónides, Buenos Aires, Argentina, and
the Ethics Committee from Hospital de Niños “Ricardo
Gutiérrez”, Buenos Aires, Argentina. Samples were used
for research purposes after obtaining the patients and/or
parents’ informed consent.
Histology, measurement of follicular density and follicle
classification
Before fixation in formalin, the fragment of tissue was
measured in length, width and thickness for volume calcu-
lation. After 24 h fixation, fragments were embedded in
paraffin, entirely cut into serial 5 μm sections and every
fifth section was stained with hematoxylin-eosin (H&E)
for routine histology. The remaining sections were kept
for immunohistochemical staining. All ovarian follicles in-
side the whole tissue fragment were counted and classified
Fig. 11 OCT3/4-A gene activity in patients that had or had not received chemotherapy. No significant statistical differences were detected
between groups; however, gene activity tends to be increased in response to chemotherapy
Fig. 10 mRNA expression in human ovary from pre- and pubertal oncological patients. Each bar represents a mean ± s.d. Different letters over
the bars indicate significant differences between samples (Tukey, α: 0,05, p < α)
Albamonte et al. Journal of Ovarian Research           (2019) 12:22 Page 12 of 16
according to Gougeon [17]. Only oocyte-containing folli-
cles were included in the counting.
Immunohistochemistry
Mounted paraffin sections were dewaxed in xylene,
rehydrated in graded alcohols and washed in distilled
water. Endogenous peroxidase activity was inhibited by
using 0.5% H2O2/methanol (v/v) for 20 min at room
temperature. Sections were then blocked for 1 h with
15% normal goat serum or normal rabbit serum in phos-
phate buffered saline (PBS) and incubated overnight at
room temperature with the 1:200 diluted primary anti-
body: goat polyclonal anti-OCT3/4, goat polyclonal
anti-VASA; goat polyclonal anti-BCL2; rabbit polyclonal
anti-BAX; goat polyclonal anti-BID; rabbit polyclonal
anti-MCL-1; rabbit polyclonal anti-FAS; rabbit poly-
clonal anti-FASL; rabbit polyclonal anti-PROCASPASE 3
and rabbit polyclonal anti-CLEAVED CASPASE 3. All
antibodies were from Santa Cruz Biotechnology (Dallas,
TX, USA) except cleaved CASPASE 3 purchased from
AbCam (Cambridge, UK). After overnight incubation,
slides were rinsed thrice in PBS and incubated for 1 h at
room temperature with the appropriate 1:200-diluted bi-
otinylated secondary antibody (Vector Labs, Peterbor-
ough, UK). After further washing in PBS, sections were
incubated for 30 min with 1:100 diluted streptavidin-per-
oxidase complexes (ABC kit, Vector Labs, UK). Sections
were then washed twice with PBS, and development of
peroxidase activity was revealed with 0.05% 3,3′-diami-
nobenzidine (w/v) and 0.1% H2O2 (v/v) in Tris-HCl. Fi-
nally, sections were washed with distilled water and
mounted in Canada balsam (Biopack, Buenos Aires,
Argentina). Negative controls were processed simultan-
eously by omitting the primary antibody and/or preincu-
bating the primary antibody with the specific
commercial synthetic peptide.
Western blot analysis of VASA, BCL2, BAX, MCL-1 and
cleaved-BID proteins
Ovarian fragments preserved at − 80 °C were homoge-
nized in ice-cold lysis buffer containing a protease in-
hibitor cocktail [0.5 mM phenylmethylsulfonyl fluoride
(PMSF); 10 mM leupeptin; 10 mM pepstatin; 10 mM
aprotinin], and centrifuged at 1.200 g at 4 °C for 10 min.
The supernatant was collected and proteins were quanti-
fied using the Bradford Protein Assay (Bio-Rad Labora-
tories, Inc., Hercules, CA, USA). Total proteins (10 μg
for BCL2, BAX and VASA; 20 μg for MCL-1 and
cleaved-BID) from tissue extracts were separated by
one-dimensional SDS-PAGE (10% for MCL-1 and
VASA; 12% for BCL2, BAX and cleaved-BID) and then
transferred onto polyvinylidene fluoride (PVDF) mem-
branes (Immobilon-P Transfer membrane, Millipore,
Billerica, MA, USA). Membranes were then blocked for
1 h in PBS + 0,1% Tween20 with bovine serum albumin
(BSA) or non-fat dry milk depending on the first anti-
body to be used (3% BSA + 3% non fat dry milk for
BAX; 5% non fat dry milk for BCL2, MCL-1 and
cleaved-BID). After that, they were incubated 1 h at
room temperature with the primary antibody (1400 di-
luted goat polyclonal anti-BCL2, 1:700 diluted rabbit
polyclonal anti-BAX, 1:600 diluted rabbit monoclonal




1 7 Knee osteosarcoma No
2 12 Acute myeloid
leukemia
First cycle of G.A.T.L.A and a second cycle of ifosfamide and carboplatin etoposide, after relapse.
3 12 Hodgkin’s lymphoma No





6 13 Inguinal synovial
sarcoma
Three cycles of ifosfamide and doxorubicin.
7 14 Rib osteosarcoma No
8 15 Hodgkin’s lymphoma No
9 16 Hodgkin’s lymphoma OPPA scheme, two cycles of vincristine, doxorubicin and procarbazine, COOP scheme and two cycles of
vincristine, procarbazine and cyclophosphamide.
10 18 Ganglioneuroblastoma Cycle 1, 2, 4 and 6 of cyclophosphamide, doxorubicin and vincristine; cycle 3 and 5 of etoposide and
cisplatin; 6 cycles of 13-cys-retinoic. Also, she received 3000 cGy radiotherapy.
11 18 Hodgkin’s lymphoma No
12 19 Myelodysplastic
síndrome
Cytarabine, idarubicine and etoposide.
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anti-cleaved-BID, 1:700 diluted rabbit polyclonal
anti-MCL-1, all antibodies from Santa Cruz Biotechnol-
ogy, Dallas, USA). Goat anti-rabbit IgG horseradish
peroxidase-conjugated secondary antibody (Bio-Rad La-
boratories, Inc., Hercules, CA, USA) was employed at a
1:3000 dilution or rabbit anti-goat IgG horseradish
peroxidase-conjugated secondary antibody (Vector Labs,
Peterborough, UK) at 1:5000 dilution. The immunoreac-
tive product was visualized using the enhanced chemilu-
minescence system ECL plus GE (Amersham, Fairfield,
Connecticut, USA). Snap-id (Millipore, Billerica, Massa-
chusetts, USA) was employed to analyze VASA expres-
sion; a 1:200 dilution for goat polyclonal anti-VASA was
used (Santa Cruz Biotecnology, Dallas, TX, USA).
Horseradish peroxidase-conjugated second antibody was
used at a 1:600 dilution. To confirm equal loading, each
membrane was analyzed for β-actin protein expression
with Snap-id, demonstrating that the band intensities
did not show significant changes between the samples
analyzed. Briefly, membranes were incubated with
monoclonal anti-β-actin (Sigma, Saint Louis, Missouri,
USA) diluted 1:20000. After washing, membranes were
incubated with a goat anti-mouse IgG (Bio-Rad, 1:600)
conjugated to peroxidase, and then revealed as described
above. Stained protein molecular weight markers were
used as standards (Fermentas, Vilnius, Lithuania). Densi-
tometry was performed on Scion Image for Windows
software (Scion Corporation 2000–2001) and VASA,
BCL2, BAX, MCL-1 L, MCL-1S and BID expression was
normalized to β-actin.
RNA isolation and real time-PCR
Samples recovered in RNA later at the surgery room were
maintained in that solution for 48 h and then stored a −
80 °C until used. Total ovary RNA was extracted with Tri-
zol (Invitrogen, Waltham, MA, USA) according to the
manufacturer’s instructions. Total RNA (3 μg) was treated
with DNAse I (Invitrogen, Waltham, MA, USA) and used
for reverse transcription in a 20 μl-reaction containing
M-MLV reverse transcriptase (200U/μl, Promega, Madi-
son, WI, USA) and random hexamers primers (Biodynam-
ics, Buenos Aires, Argentina). Reverse-transcribed cDNA
was employed for quantitative polymerase chain reaction
(PCR) using SYBR Green PCR Master Mix and specific
forward (F) and reverse (R) primers (Table 3), in a Strata-
gene MPX500 cycler (Stratagene, La Jolla, CA, USA).
Primers were used at a concentration of 0.3 μM in each
reaction. The cycling conditions were as follows: step 1,
10min at 95 °C; step 2, 30s at 95 °C; step 3, 30s at 55 °C;
step 4, 30s at 60 °C, repeating steps 2 to 4 forty-five times.
Table 3 Oligonucleotide primers used for real-time PCR amplification of cDNA obtained after reverse transcription from adolescent
human ovary RNA
GENE PRIMERS (5′→ 3′)
F: forward. R: reverse
AMPLIFIED
PRODUCT (bp)
BAX (NM_138761.3)* F: GCATCGGGGACGAACTGG
R: GTCCCAAAGTAGGAGAGGA
307
BCL2 (NM_000633.2) F: GCCTTCTTTGAGTTCGG
R: GGGTGATGCAAGCTCC
250
BID (NM_197966.2) F: CCTTGCTCCGTGATGTCTTTC
R: TCCGTTCAGTCCATCCCATTT
100
MCL-1 L (NM_021960.4) F: TAAGGACAAAACGGGACTGG
R: ACCAGCTCCTACTCCAGCAA
137






FAS (NM_000043.4) F: CACTATTGCTGGAGTCAG
R: CTGAGTCACTAGTAATGTCC
266
FAS-L (NM_000639.1) F: TCAATGAAACTGGGCTGTACTTT
R: AGAGTTCCTCATGTAGACCTTGT
101
CASPASE-3 (NM_004346.3) F: CCTCTTCCCCCATTCTCAT
R: GAGTCCATTGATTCGCTTCC
119
VASA (NM_024415.2) F: AGAAAGTAGTGATACTCAAGGACCAA R: TGACAGAGATTAGCTTCTTCAAAAGT 199
OCT3/4 A (NM_002701.3) F: CTCCTGGAGGGCCAGGAATC
R: CCACATCGGCCTGTGTATAT
341
OCT3/4 B (NM_203289.4) F: ATGCATGAGTCAGTGAACAG
R: CCACATCGGCCTGTGTATAT
263
Β-actin (NM_001101.3) F: CTTCCCCTCCATCGTGGG
R: GTGGTACGGCCAGAGGCG
357
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Data from the reaction were collected and analyzed by the
complementary computer software (MxPro3005P v4.10
Build 389, Schema 85, Stratagene, La Jolla, CA, USA).
Melting curves were run to confirm specificity of the
signal. Relative quantitation of gene expression was per-
formed using standard curves and normalized to β-actin
in each sample. For assessment of quantitative differences
in the cDNA target between samples, the mathematical
model of Pfaffl was applied. The expression ratio was
determined for each sample by calculating (Etarget)
ΔCt(tar-
get)/(EGβACTIN)
ΔCt(βactin), where E is the efficiency of the
primer set and CT is threshold cycle with ΔCt = Ct
(normalization cDNA) - Ct (experimental cDNA). The amplification
efficiency of each primer set was calculated from the slope
of a standard amplification curve of log (ng cDNA) per re-
action vs. Ct value (E = 10-(1/slope)). Efficiencies of 2 ± 0.1
were considered optimal.
Terminal deoxynucleotidyl transferase-mediated dUTP
nick-end labelling
Detection of DNA fragmentation was performed in
formalin-fixed/paraffin-embedded sections by TUNEL
technique, using the ‘In Situ Cell Death Detection Kit’
(Roche Diagnostics, Germany) with fluorescein-tagged
nucleotides. The procedure followed the manufacturers’
recommendations. Treated sections were examined in
an Olympus BX40 microscope by conventional epifluor-
escence with ultraviolet illumination. In order to confirm
negative results, TUNEL-processed sections were incu-
bated with 10 UI/ml DNase II (Sigma Chemical Co.,
USA) in 50mM Tris–HCl, pH 7.5, 10 mM Mg2Cl and 1
mg/ml BSA for 10min at room temperature. After incu-
bation, slides were thoroughly rinsed and treated again
according to the TUNEL protocol. Images were captured
with an Olympus Camedia C-5060 camera.
Statistical analysis
Mean and standard error (SEM) were calculated and
the InfoStat Software (Version 2012, Grupo InfoStat,
Universidad Nacional de Córdoba, Córdoba, Argentina)
was used for one-way analysis of variance. A log10
transformation of data was done. Tukey’s test was used
when differences between more than two groups were
compared. A p-value of less than 0.05 was considered
statistically significant.
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